Can-C™ Eye Drops and Their Use in Treating Cataracts! By Leslie Burke At Isnare.com Ezine Articles

Can-C™ is a product that has been proven effective in reversing and controlling the age-related disorder, senile cataract. Developed and patented by Innovative Vision Products, Can-C contains the active ingredient, special form of N-acetylcarnosine or NAC, a dipeptide that can be found naturally in the human body. Its parent compound, carnosine is a natural component in food and human cells such as the heart, skeletal muscles, and the brain.

N-Acetylcarnosine is an important molecule that plays an important role in the prevention of age-related diseases. It acts as an antioxidant as well as an inhibitor of the age related glycation process.

Although carnosine is naturally present in the body, its amount is affected by the age of the person. As the human body ages, the level of carnosine in the body decreases. When this happens, age-related disorders like senile cataracts begin to present.

Cataract is a visual impairment disease in which the patient complains of blurriness, glare sensitivity and diminished visual ocuity, which can ultimately lead to blindness. The problem happens with the aged eye lens. The clear lens of the eye develops an opacity which progressively hinders vision. Upon doctor’s advice, the usual treatment is eye surgery to remove the cloudy lens and replacing it with an artificial one.

However, as with any surgery, there are risks to the patient which can vary from bleeding to having post surgery eye infection. But not all types of cataracts need surgery now that there is a non invasive option for dealing with cataract.

With the breakthrough of effectively re-introducing carnosine into the cells of the eye topically, thousands are now choosing a more natural approach to treating cataract..

Can-C™ which is available as an eye drop provides the most direct delivery route of carnosine to the aqueous humor of the eye. The ‘N-acetyl’ part of the molecule is what makes carnosine soluble in lipids. This means the ‘N-acetyl’ component helps in the absorption of the molecule into the lipid membranes of the retinal, corneal and lens cells. Once N-acetylcarnosine is delivered into the cell, it then releases the basic component, carnosine where it then exerts its beneficial antioxidant effects, with no side effects.

The use of Can-C™ in treating cataracts has been studied over the last twelve years now by a leading group of Russian medical researchers. Over that time frame this amazing antioxidant eye drop has generated thousands of reports of safe and effective cataract reversal both in humans and animals.

The human trial results revealed that those affected for less than 7 years had the fastest and greatest improvement, those with cataracts for 7-15 years still had good results and those that had the disease for over 15 years had the least beneficial results but still obtained measurable visual improvement.

The recommended dose for treatment is 2 drops, twice a day applied to the affected eye with visual ocuity improvements in just 90 days time. For optimal results, it’s recommended that application is continue for a period 6-12 months. Then for preventing the recurrence of cataract, a dosage of 1 drop a day on the eye is recommend as an on-going regimen.

This article is free to republish provided the authors resource box remains intact.

Published At: Isnare Free Articles Directory http://www.isnare.com
Permanent Link: http://www.isnare.com/?aid=295775&ca=Medicines+and+Remedies

Important Notice DISCLAIMER: All information, content, and data in this article are sole opinions and/or findings of the individual user or organization that registered and submitted this article at Isnare.com without any fee. The article is strictly for educational or entertainment purposes only and should not be used in any way, implemented or applied without consultation from a professional. We at Isnare.com do not, in anyway, contribute or include our own findings, facts and opinions in any articles presented in this site. Publishing this article does not constitute Isnare.com's support or sponsorship for this article. Isnare.com is an article publishing service. Please read our Terms of Service for more information.